|
|
Volumn 61, Issue 21, 2004, Pages 2234-2238
|
|
MI risk prompts rofecoxib withdrawal
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABACAVIR PLUS LAMIVUDINE;
ACETYLSALICYLIC ACID;
CELECOXIB;
CODEINE;
CODEPREX;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
LANSOPRAZOLE;
NAPROXEN;
PLACEBO;
ROFECOXIB;
SERTACONAZOLE;
URSODEOXYCHOLIC ACID;
VALDECOXIB;
ADENOMATOUS POLYP;
ALLERGIC RHINITIS;
BLOOD PRESSURE;
CARDIOVASCULAR RISK;
COUGHING;
DECISION MAKING;
DRUG EFFICACY;
DRUG WITHDRAWAL;
FOOD AND DRUG ADMINISTRATION;
HEART INFARCTION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LOW DRUG DOSE;
MEDICAL EXPERT;
NOTE;
OSTEOARTHRITIS;
PRIORITY JOURNAL;
REFLUX ESOPHAGITIS;
SNEEZING;
THROMBOCYTE AGGREGATION;
THROMBOEMBOLISM;
TINEA PEDIS;
|
|
EID: 12544251638
PISSN: 10792082
EISSN: None
Source Type: Journal
DOI: 10.1093/ajhp/61.21.2234 Document Type: Note |
|
Times cited : (10)
|
|
References (0)
|